Technical Analysis for TLSI - TriSalus Life Sciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 9.71 | 0.94% | 0.09 |
TLSI closed up 0.94 percent on Tuesday, May 7, 2024, on 49 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Shooting Star Candlestick | Bearish | 0.00% | |
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Doji - Bearish? | Reversal | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| 20 DMA Resistance | Bearish | 0.94% | |
| 50 DMA Support | Bullish | 0.94% | |
| Multiple of Ten Bearish | Other | 0.94% | |
| Gapped Up | Strength | 0.94% | |
| 20 DMA Resistance | Bearish | 0.94% | |
| Crossed Above 50 DMA | Bullish | 0.94% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 14 hours ago |
| Up 3% | about 14 hours ago |
| Up 2% | about 14 hours ago |
| Rose Above 20 DMA | about 15 hours ago |
| Rose Above 10 DMA | about 15 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
Sector: Healthcare
Industry: Medical Devices
Keywords: Cancer Immunotherapy Immunotherapies Colorectal Cancer Pancreatic Cancer Hepatology Hepatocellular Carcinoma Uveal Melanoma Cholangiocarcinoma Intrahepatic Cholangiocarcinoma
Classification
Sector: Healthcare
Industry: Medical Devices
Keywords: Cancer Immunotherapy Immunotherapies Colorectal Cancer Pancreatic Cancer Hepatology Hepatocellular Carcinoma Uveal Melanoma Cholangiocarcinoma Intrahepatic Cholangiocarcinoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 16.24 |
| 52 Week Low | 3.33 |
| Average Volume | 47,577 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 9.63 |
| 20-Day Moving Average | 9.64 |
| 10-Day Moving Average | 9.58 |
| Average True Range | 0.49 |
| RSI (14) | 51.92 |
| ADX | 21.0 |
| +DI | 18.13 |
| -DI | 9.84 |
| Chandelier Exit (Long, 3 ATRs) | 8.96 |
| Chandelier Exit (Short, 3 ATRs) | 10.57 |
| Upper Bollinger Bands | 10.17 |
| Lower Bollinger Band | 9.11 |
| Percent B (%b) | 0.56 |
| BandWidth | 11.02 |
| MACD Line | -0.02 |
| MACD Signal Line | -0.01 |
| MACD Histogram | -0.0168 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 10.35 | ||||
| Resistance 3 (R3) | 10.41 | 10.26 | 10.25 | ||
| Resistance 2 (R2) | 10.26 | 10.09 | 10.23 | 10.21 | |
| Resistance 1 (R1) | 9.98 | 9.99 | 10.12 | 9.92 | 10.18 |
| Pivot Point | 9.83 | 9.83 | 9.90 | 9.80 | 9.83 |
| Support 1 (S1) | 9.55 | 9.66 | 9.69 | 9.50 | 9.24 |
| Support 2 (S2) | 9.40 | 9.56 | 9.37 | 9.21 | |
| Support 3 (S3) | 9.12 | 9.40 | 9.17 | ||
| Support 4 (S4) | 9.07 |
